VCM
DNLI icon

Versant Capital Management’s Denali Therapeutics DNLI Stock Holding History

Versant Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$33.2K Sell
1,604
-29
-2% -$679 ﹤0.01% 1684
2026
Q2 		$42K Buy
1,633
+157
+11% +$3.23K ﹤0.01% 1492
2026
Q1 		$28.3K Hold
1,476
– – ﹤0.01% 1611
2025
Q4 		$24.4K Hold
1,476
– – ﹤0.01% 1520
2025
Q3 		$21.4K Buy
1,476
+190
+15% +$2.73K ﹤0.01% 1541
2025
Q2 		$18K Buy
1,286
+570
+80% +$8.02K ﹤0.01% 1590
2025
Q1 		$9.73K Buy
716
+513
+253% +$9.83K ﹤0.01% 1739
2024
Q4 		$4.14K Hold
203
– – ﹤0.01% 1848
2024
Q3 		$5.91K Buy
203
+102
+101% +$2.53K ﹤0.01% 1242
2024
Q2 		$2.35K Sell
101
-8
-7% -$154 ﹤0.01% 1460
2024
Q1 		$2.24K Buy
109
+101
+1,263% +$1.9K ﹤0.01% 1313
2023
Q4 		$172 Buy
+8
New +$158 ﹤0.01% 1880
2023
Q3 		– Sell
-18
Closed -$531 – 1966
2023
Q2 		$531 Buy
+18
New +$506 ﹤0.01% 1820
2019
Q4 		– Sell
-39
Closed – – 1397
2019
Q3 		$0 Buy
+39
New +$745 ﹤0.01% 1408

Other funds holding DNLI

BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Versant Capital Management's DNLI Position: Q3 2026 in Review

Versant Capital Management reduced its Denali Therapeutics (DNLI) stake by 1.8% in Q3 2026, selling an estimated $679 and leaving 1,604 shares worth $33.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1684.

Versant Capital Management first reported a position in DNLI in Q3 2019 and has held it in 14 quarters since. The position peaked at $42K in Q2 2026. 5 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Versant Capital Management held 1,604 shares of Denali Therapeutics worth $33.2K as of Q3 2026.
  • Versant Capital Management sold 29 Denali Therapeutics shares in Q3 2026, an estimated $679.
  • Denali Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1684 holding.
  • Versant Capital Management first reported a position in Denali Therapeutics in Q3 2019 and has held it in 14 quarters since.
  • Versant Capital Management's Denali Therapeutics position peaked at $42K in Q2 2026.
  • 5 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.